CG Oncology vs Ocugen
Ocugen reported revenue of $4 million in fiscal 2025, about the same as CG Oncology's $4 million in fiscal 2025. CG Oncology's revenue grew 254.7% in its latest year, and Ocugen's grew 8.8%. CG Oncology had an operating margin of -4722.1%, against -1425.7% at Ocugen. Free cash flow was −$132 million at CG Oncology and −$57 million at Ocugen.
Side by side
| CG Oncology | Ocugen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $4M |
| Revenue growth | 254.7% | 8.8% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −4,722.1% | −1,425.7% |
| Net margin | −3,985.0% | −1,537.4% |
| Free cash flow | −$132M | −$57M |
| Free cash flow margin | −3,279.2% | −1,295.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.7% | — |
| Last close | $81.90 | $0.73 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $27.5 million, sold $4.8 million | bought $25,830, sold $589,110 |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CG OncologyOcugen
Operating margin
Percent of revenue
CG OncologyOcugen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CG OncologyOcugen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CG Oncology and Ocugen pages.